- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
- Biomarker-based Study in R/M SCCHN
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.